Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Hiroji IwataRikiya NakamuraNorikazu MasudaToshinari YamashitaYutaka YamamotoKokoro KobayashiJunji TsurutaniTsutomu IwasaKan YonemoriKenji TamuraTomoyuki ArugaEriko TokunagaKoji KanekoMin-Jung LeeAkira YunoAzusa KawabataToshihiro SeikeAyumi KanedaYozo NishimuraJane B TrepelShigehira SajiPublished in: Japanese journal of clinical oncology (2022)
In Japanese patients, the safety of entinostat plus exemestane was acceptable and progression-free survival was prolonged, although not significantly. Exploratory analyses identified potential biomarkers, including lysine acetylation, of efficacy.